--- title: "Stereotaxis (NYSEAMERICAN:STXS) Trading Down 2.3% - Here's Why" type: "News" locale: "en" url: "https://longbridge.com/en/news/299397928.md" description: "Stereotaxis (STXS) shares fell 2.3% to $1.29 on Thursday, with trading volume up 24%. Analysts at Citizens JMP and TD Cowen cut price targets to $3.00, while Citigroup maintained an 'outperform' rating. The consensus remains a 'Buy' with an average target of $3.50. Recent quarterly earnings showed ($0.05) EPS, meeting estimates, but revenue missed at $7.67 million. Institutional investors increased stakes, holding 45.35% of the stock." datetime: "2026-09-18T04:40:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/299397928.md) - [en](https://longbridge.com/en/news/299397928.md) - [zh-HK](https://longbridge.com/zh-HK/news/299397928.md) generator: "portal-rs" --- # Stereotaxis (NYSEAMERICAN:STXS) Trading Down 2.3% - Here's Why Stereotaxis Inc. (NYSEAMERICAN:STXS - Get Free Report)'s share price fell 2.3% during trading on Thursday . The stock traded as low as $1.29 and last traded at $1.29. 598,312 shares changed hands during mid-day trading, an increase of 24% from the average session volume of 481,507 shares. The stock had previously closed at $1.32. ## Analyst Ratings Changes - 3 Underrated Robotics Stocks Poised for Huge Gains A number of equities research analysts have weighed in on the stock. Citizens Jmp cut their price target on shares of Stereotaxis from $4.00 to $3.00 and set a "market outperform" rating for the company in a report on Thursday, August 27th. Citigroup reiterated an "outperform" rating on shares of Stereotaxis in a report on Thursday, August 27th. Finally, TD Cowen cut their target price on shares of Stereotaxis from $5.00 to $3.00 and set a "buy" rating for the company in a research note on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $3.50. **Check Out Our Latest Research Report on STXS** ## Stereotaxis Trading Down 2.3% The stock has a 50-day moving average of $1.41 and a two-hundred day moving average of $1.72. The firm has a market cap of $129.26 million, a price-to-earnings ratio of -5.37 and a beta of 1.43. Stereotaxis (NYSEAMERICAN:STXS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, meeting analysts' consensus estimates of ($0.05). Stereotaxis had a negative net margin of 74.24% and a negative return on equity of 130.84%. The company had revenue of $7.67 million during the quarter, compared to analyst estimates of $8.35 million. Sell-side analysts expect that Stereotaxis Inc. will post -0.22 EPS for the current fiscal year. ## Hedge Funds Weigh In On Stereotaxis A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legato Capital Management LLC boosted its position in shares of Stereotaxis by 9.6% in the fourth quarter. Legato Capital Management LLC now owns 504,506 shares of the company's stock worth $1,160,000 after buying an additional 44,207 shares during the period. Leonteq Securities AG acquired a new position in Stereotaxis during the fourth quarter valued at $172,000. Bank of New York Mellon Corp purchased a new stake in Stereotaxis in the 2nd quarter worth about $364,000. Sei Investments Co. lifted its stake in Stereotaxis by 108.9% in the 1st quarter. Sei Investments Co. now owns 518,884 shares of the company's stock worth $955,000 after acquiring an additional 270,443 shares in the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new stake in Stereotaxis during the 1st quarter worth about $700,000. Institutional investors and hedge funds own 45.35% of the company's stock. ## About Stereotaxis (Get Free Report) Stereotaxis, Inc develops robotic technologies for the treatment of cardiac arrhythmias and other conditions addressed through minimally invasive endovascular procedures. Its systems are designed to help physicians navigate specialized catheters through the cardiovascular system with computerized control and magnetic guidance, supporting procedures such as electrophysiology studies and catheter ablation. The company's portfolio includes the Genesis Robotic Magnetic Navigation system, which uses externally controlled magnetic fields to guide compatible catheters, as well as related workflow, visualization and information-management technologies. ## Further Reading - Five stocks we like better than Stereotaxis - Aeluma’s Selloff Could Be Setting Up Its Next Big Move - Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip? - The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks - The Fed’s Rate Hike Could Backfire If Oil Prices Collapse *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Stereotaxis Right Now? Before you consider Stereotaxis, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stereotaxis wasn't on the list. While Stereotaxis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ### Related Stocks - [STXS.US](https://longbridge.com/en/quote/STXS.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [SEIC.US](https://longbridge.com/en/quote/SEIC.US.md) - [ALMU.US](https://longbridge.com/en/quote/ALMU.US.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) ## Related News & Research - [Citizens Jmp Issues Pessimistic Forecast for Stereotaxis (NYSEAMERICAN:STXS) Stock Price](https://longbridge.com/en/news/297201385.md) - [Stereotaxis to showcase digital, AI and automation tools at Heart Rhythm Society’s HRX conference](https://longbridge.com/en/news/299179059.md) - [Tesla Analyst Raises Revenues Estimates Ahead Of Q3 Results](https://longbridge.com/en/news/302450176.md) - [Micron Stock Moves Higher: What's Going On?](https://longbridge.com/en/news/302449704.md) - [Nvidia Reportedly Just Landed $35 Billion In Chip Orders From Chinese Companies. Here's Why That Could Be Great News for the Stock](https://longbridge.com/en/news/302459774.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**